Share on Facebook Share on Twitter Email
Answers.com

insulin

 
Dictionary: in·su·lin   (ĭn'sə-lĭn) pronunciation
n.
  1. A polypeptide hormone secreted by the islets of Langerhans and functioning in the regulation of the metabolism of carbohydrates and fats, especially the conversion of glucose to glycogen, which lowers the blood glucose level.
  2. Any of various pharmaceutical preparations containing this hormone that are derived from the pancreas of certain animals or produced through genetic engineering and are used in the medical treatment and management of diabetes mellitus (type I).

[New Latin īnsula, island (of Langerhans) (from Latin, island) + -IN.]


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics

Polypeptide hormone (see peptide) that regulates blood glucose levels. Secreted by the islets of Langerhans (see Langerhans, islets of) in the pancreas when blood glucose rises, as after a meal, it helps transfer the glucose into the body's cells to be oxidized (see oxidation-reduction) for energy or converted and stored as fatty acids or glycogen. When blood glucose falls, insulin secretion stops and the liver releases more glucose into the blood. Insulin has various related functions in the liver, muscles, and other tissues, controlling the balance of glucose with related compounds. Insulin-related disorders include diabetes mellitus and hypoglycemia. Frederick Banting and J.J.R. Macleod won a Nobel Prize in 1923 for discovering insulin, and Frederick Sanger won one in 1958 for determining its amino acid sequence.

For more information on insulin, visit Britannica.com.

How Products are Made: How is insulin made?
Top

Background

Insulin is a hormone that regulates the amount of glucose (sugar) in the blood and is required for the body to function normally. Insulin is produced by cells in the pancreas, called the islets of Langerhans. These cells continuously release a small amount of insulin into the body, but they release surges of the hormone in response to a rise in the blood glucose level.

Certain cells in the body change the food ingested into energy, or blood glucose, that cells can use. Every time a person eats, the blood glucose rises. Raised blood glucose triggers the cells in the islets of Langerhans to release the necessary amount of insulin. Insulin allows the blood glucose to be transported from the blood into the cells. Cells have an outer wall, called a membrane, that controls what enters and exits the cell. Researchers do not yet know exactly how insulin works, but they do know insulin binds to receptors on the cell's membrane. This activates a set of transport molecules so that glucose and proteins can enter the cell. The cells can then use the glucose as energy to carry out its functions. Once transported into the cell, the blood glucose level is returned to normal within hours.

Without insulin, the blood glucose builds up in the blood and the cells are starved of their energy source. Some of the symptoms that may occur include fatigue, constant infections, blurred eye sight, numbness, tingling in the hands or legs, increased thirst, and slowed healing of bruises or cuts. The cells will begin to use fat, the energy source stored for emergencies. When this happens for too long a time the body produces ketones, chemicals produced by the liver. Ketones can poison and kill cells if they build up in the body over an extended period of time. This can lead to serious illness and coma.

People who do not produce the necessary amount of insulin have diabetes. There are two general types of diabetes. The most severe type, known as Type I or juvenile-onset diabetes, is when the body does not produce any insulin. Type I diabetics usually inject themselves with different types of insulin three to four times daily. Dosage is taken based on the person's blood glucose reading, taken from a glucose meter. Type II diabetics produce some insulin, but it is either not enough or their cells do not respond normally to insulin. This usually occurs in obese or middle aged and older people. Type II diabetics do not necessarily need to take insulin, but they may inject insulin once or twice a day.

There are four main types of insulin manufactured based upon how soon the insulin starts working, when it peaks, and how long it lasts in the body. According to the American Diabetes Association, rapid-acting insulin reaches the blood within 15 minutes, peaks at 30-90 minutes, and may last five hours. Short-acting insulin reaches the blood within 30 minutes, it peaks about two to four hours later and stays in the blood for four to eight hours. Intermediate-acting insulin reaches the blood two to six hours after injection, peaks four to 14 hours later, and can last in the blood for 14-20 hours. And long-acting insulin takes six to 14 hours to start working, it has a small peak soon after, and stays in the blood for 20-24 hours. Diabetics each have different responses to and needs for insulin so there is no one type that works best for everyone. Some insulin is sold with two of the types mixed together in one bottle.

History

If the body does not produce any or enough insulin, people need to take a manufactured version of it. The major use of producing insulin is for diabetics who do not make enough or any insulin naturally.

Before researchers discovered how to produce insulin, people who suffered from Type I diabetes had no chance for a healthy life. Then in 1921, Canadian scientists Frederick G. Banting and Charles H. Best successfully purified insulin from a dog's pancreas. Over the years scientists made continual improvements in producing insulin. In 1936, researchers found a way to make insulin with a slower release in the blood. They added a protein found in fish sperm, protamine, which the body breaks down slowly. One injection lasted 36 hours. Another breakthrough came in 1950 when researchers produced a type of insulin that acted slightly faster and does not remain in the bloodstream as long. In the 1970s, researchers began to try and produce an insulin that more mimicked how the body's natural insulin worked: releasing a small amount of insulin all day with surges occurring at mealtimes.

Researchers continued to improve insulin but the basic production method remained the same for decades. Insulin was extracted from the pancreas of cattle and pigs and purified. The chemical structure of insulin in these animals is only slightly different than human insulin, which is why it functions so well in the human body. (Although some people had negative immune system or allergic reactions.) Then in the early 1980s biotechnology revolutionized insulin synthesis. Researchers had already decoded the chemical structure of insulin in the mid1950s. They soon determined the exact location of the insulin gene at the top of chromosome 11. By 1977, a research team had spliced a rat insulin gene into a bacterium that then produced insulin.

In the 1980s, researchers used genetic engineering to manufacture a human insulin. In 1982, the Eli Lilly Corporation produced a human insulin that became the first approved genetically engineered pharmaceutical product. Without needing to depend on animals, researchers could produce genetically engineered insulin in unlimited supplies. It also did not contain any of the animal contaminants. Using human insulin also took away any concerns about transferring any potential animal diseases into the insulin. While companies still sell a small amount of insulin produced from animals—mostly porcine—from the 1980s onwards, insulin users increasingly moved to a form of human insulin created through recombinant DNA technology. According to the Eli Lilly Corporation, in 2001 95% of insulin users in most parts of the world take some form of human insulin. Some companies have stopped producing animal insulin completely. Companies are focusing on synthesizing human insulin and insulin analogs, a modification of the insulin molecule in some way.

Raw Materials

Human insulin is grown in the lab inside common bacteria. Escherichia coli is by far the most widely used type of bacterium, but yeast is also used.

Researchers need the human protein that produces insulin. Manufacturers get this through an amino-acid sequencing machine that synthesizes the DNA. Manufacturers know the exact order of insulin's amino acids (the nitrogen-based molecules that line up to make up proteins). There are 20 common amino acids. Manufacturers input insulin's amino acids, and the sequencing machine connects the amino acids together. Also necessary to synthesize insulin are large tanks to grow the bacteria, and nutrients are needed for the bacteria to grow. Several instruments are necessary to separate and purify the DNA such as a centrifuge, along with various chromatography and x-ray crystallography instruments.

The Manufacturing
Process

Synthesizing human insulin is a multi-step biochemical process that depends on basic recombinant DNA techniques and an understanding of the insulin gene. DNA carries the instructions for how the body works and one small segment of the DNA, the insulin gene, codes for the protein insulin. Manufacturers manipulate the biological precursor to insulin so that it grows inside simple bacteria. While manufacturers each have their own variations, there are two basic methods to manufacture human insulin.

Working with human insulin

  • The insulin gene is a protein consisting of two separate chains of amino acids, an A above a B chain, that are held together with bonds. Amino acids are the basic units that build all proteins. The insulin A chain consists of 21 amino acids and the B chain has 30.
  • Before becoming an active insulin protein, insulin is first produced as preproinsulin. This is one single long protein chain with the A and B chains not yet separated, a section in the middle linking the chains together and a signal sequence at one end telling the protein when to start secreting outside the cell. After preproinsulin, the chain evolves into proinsulin, still a single chain but without the signaling sequence. Then comes the active protein insulin, the protein without the section linking the A and B chains. At each step, the protein needs specific enzymes (proteins that carry out chemical reactions) to produce the next form of insulin.

STARTING WITH A AND B

  • One method of manufacturing insulin is to grow the two insulin chains separately. This will avoid manufacturing each of the specific enzymes needed. Manufacturers need the two mini-genes: one that produces the A chain and one for the B chain. Since the exact DNA sequence of each chain is known, they synthesize each mini-gene's DNA in an amino acid sequencing machine.
  • These two DNA molecules are then inserted into plasmids, small circular pieces of DNA that are more readily taken up by the host's DNA.
  • Manufacturers first insert the plasmids into a non-harmful type of the bacterium E. coli. They insert it next to the lacZ gene. LacZ encodes for 8-galactosidase, a gene widely used in recombinant DNA procedures because it is easy to find and cut, allowing the insulin to be readily removed so that it does not get lost in the bacterium's DNA. Next to this gene is the amino acid methionine, which starts the protein formation.
  • The recombinant, newly formed, plasmids are mixed up with the bacterial cells. Plasmids enter the bacteria in a process called transfection. Manufacturers can add to the cells DNA ligase, an enzyme that acts like glue to help the plasmid stick to the bacterium's DNA.
  • The bacteria synthesizing the insulin then undergo a fermentation process. They are grown at optimal temperatures in large tanks in manufacturing plants. The millions of bacteria replicate roughly every 20 minutes through cell mitosis, and each expresses the insulin gene.
  • After multiplying, the cells are taken out of the tanks and broken open to extract the DNA. One common way this is done is by first adding a mixture of lysozome that digest the outer layer of the cell wall, then adding a detergent mixture that separates the fatty cell wall membrane. The bacterium's DNA is then treated with cyanogen bromide, a reagent that splits protein chains at the methionine residues. This separates the insulin chains from the rest of the DNA.
  • The two chains are then mixed together and joined by disulfide bonds through the reduction-reoxidation reaction. An oxidizing agent (a material that causes oxidization or the transfer of an electron) is added. The batch is then placed in a centrifuge, a mechanical device that spins quickly to separate cell components by size and density.
  • The DNA mixture is then purified so that only the insulin chains remain. Manufacturers can purify the mixture through several chromatography, or separation, techniques that exploit differences in the molecule's charge, size, and affinity to water. Procedures used include an ion-exchange column, reverse-phase high performance liquid chromatography, and a gel filtration chromatography column. Manufacturers can test insulin batches to ensure none of the bacteria's E. coli proteins are mixed in with the insulin. They use a marker protein that lets them detect E. coli DNA. They can then determine that the purification process removes the E. coli bacteria.

PROINSULIN PROCESS

  • Starting in 1986, manufacturers began to use another method to synthesize human insulin. They started with the direct precursor to the insulin gene, proinsulin. Many of the steps are the same as when producing insulin with the A and B chains, except in this method the amino acid machine synthesizes the proinsulin gene.
  • The sequence that codes for proinsulin is inserted into the non-pathogenic E. coli bacteria. The bacteria go through the fermentation process where it reproduces and produces proinsulin. Then the connecting sequence between the A and B chains is spliced away with an enzyme and the resulting insulin is purified.
  • At the end of the manufacturing process ingredients are added to insulin to prevent bacteria and help maintain a neutral balance between acids and bases. Ingredients are also added to intermediate and long-acting insulin to produce the desired duration type of insulin. This is the traditional method of producing longer-acting insulin. Manufacturers add ingredients to the purified insulin that prolong their actions, such as zinc oxide. These additives delay absorption in the body. Additives vary among different brands of the same type of insulin.

Analog insulin

In the mid 1990s, researchers began to improve the way human insulin works in the body by changing its amino acid sequence and creating an analog, a chemical substance that mimics another substance well enough that it fools the cell. Analog insulin clumps less and disperses more readily into the blood, allowing the insulin to start working in the body minutes after an injection. There are several different analog insulin. Humulin insulin does not have strong bonds with other insulin and thus, is absorbed quickly. Another insulin analog, called Glargine, changes the chemical structure of the protein to make it have a relatively constant release over 24 hours with no pronounced peaks.

Instead of synthesizing the exact DNA sequence for insulin, manufacturers synthesize an insulin gene where the sequence is slightly altered. The change causes the resulting proteins to repel each other, which causes less clumping. Using this changed DNA sequence, the manufacturing process is similar to the recombinant DNA process described.

Quality Control

After synthesizing the human insulin, the structure and purity of the insulin batches are tested through several different methods. High performance liquid chromatography is used to determine if there are any impurities in the insulin. Other separation techniques, such as X-ray crystallography, gel filtration, and amino acid sequencing, are also performed. Manufacturers also test the vial's packaging to ensure it is sealed properly.

Manufacturing for human insulin must comply with National Institutes of Health procedures for large-scale operations. The United States Food and Drug Administration must approve all manufactured insulin.

The Future

The future of insulin holds many possibilities. Since insulin was first synthesized, diabetics needed to regularly inject the liquid insulin with a syringe directly into their bloodstream. This allows the insulin to enter the blood immediately. For many years it was the only way known to move the intact insulin protein into the body. In the 1990s, researchers began to make inroads in synthesizing various devices and forms of insulin that diabetics can use in an alternate drug delivery system.

Manufacturers are currently producing several relatively new drug delivery devices. Insulin pens look like a writing pen. A cartridge holds the insulin and the tip is the needle. The user set a dose, inserts the needle into the skin, and presses a button to inject the insulin. With pens there is no need to use a vial of insulin. However, pens require inserting separate tips before each injection. Another downside is that the pen does not allow users to mix insulin types, and not all insulin is available.

For people who hate needles an alternate to the pen is the jet-injector. Looking similar to the pens, jet injectors use pressure to propel a tiny stream of insulin through the skin. These devices are not as widely used as the pen, and they can cause bruising at the input point.

The insulin pump allows a controlled release in the body. This is a computerized pump, about the size of a beeper, that diabetics can wear on their belt or in their pocket. The pump has a small flexible tube that is inserted just under the surface of the diabetic's skin. The diabetic sets the pump to deliver a steady, measured dose of insulin throughout the day, increasing the amount right before eating. This mimics the body's normal release of insulin. Manufacturers have produced insulin pumps since the 1980s but advances in the late 1990s and early twenty-first century have made them increasingly easier to use and more popular. Researchers are exploring the possibility of implantable insulin pumps. Diabetics would control these devices through an external remote control.

Researchers are exploring other drug-delivery options. Ingesting insulin through pills is one possibility. The challenge with edible insulin is that the stomach's high acidic environment destroys the protein before it can move into the blood. Researchers are working on coating insulin with plastic the width of a few human hairs. The coverings would protect the drugs from the stomach's acid.

In 2001 promising tests are occurring on inhaled insulin devices and manufacturers could begin producing the products within the next few years. Since insulin is a relatively large protein, it does not permeate into the lungs. Researchers of inhaled insulin are working to create insulin particles that are small enough to reach the deep lung. The particles can then pass into the bloodstream. Researchers are testing several inhalation devices much like that of an asthma inhaler.

Another form of aerosol device undergoing tests will administer insulin to the inner cheek. Known as buccal (cheek) insulin, diabetics will spray the insulin onto the inside of their cheek. It is then absorbed through the inner cheek wall.

Insulin patches are another drug delivery system in development. Patches would release insulin continuously into the bloodstream. Users would pull a tab on the patch to release more insulin before meals. The challenge is finding a way to have insulin pass through the skin. Ultrasound is one method researchers are investigating. These low frequency sound waves could change the skin's permeability and allow insulin to pass.

Other research has the potential to discontinue the need for manufacturers to synthesize insulin. Researchers are working on creating the cells that produce insulin in the laboratory. The thought is that physicians can someday replace the non-working pancreas cells with insulin-producing cells. Another hope for diabetics is gene therapy. Scientists are working on correcting the insulin gene's mutation so that diabetics would be able to produce insulin on their own.

Where to Learn More

Books

Clark, David P, and Lonnie D. Russell. Molecular Biology Made Simple and Fun. 2nd ed. Vienna, IL: Cache River Press, 2000.

Considine, Douglas M., ed. Van Nostrand's Scientific Encyclopedia. 8th ed. New York: International Thomson Publishing Inc., 1995.

Periodicals

Dinsmoor, Robert S. "Insulin: A Never-ending Evolution." Countdown (Spring 2001).

Other

Diabetes Digest Web Page. 15 November 2001. <http://www.diabetesdigest.com>.

Discovery of Insulin Web Page. 16 November 2001. <http://web.idirect.com/~discover>.

Eli Lilly Corporation. Humulin and Humalog Development. CD-ROM, 2001.

Eli Lilly Diabetes Web Page. 16 November 2001. <http://www.lillydiabetes.com>.

Novo Nordisk Diabetes Web Page. 15 November 2001. <http://www.novonet.co.nz>.

[Article by: M. Rae Nelson]


Produced and secreted by the beta cells of the islets (insulae) of Langerhans of the pancreas, the hormone which regulates the use and storage of foodstuffs, especially the carbohydrates. Chemically insulin is a small, simple protein. Insulins from various species differ in the composition; these differences account for the fact that diabetics treated with animal insulins develop antibodies which may sometimes interfere with the action of the hormone. The structure has been verified by synthesis of insulin from pure amino acids in the laboratory. See also Carbohydrate metabolism; Immunology; Pancreas.

Insulin, being a polypeptide, can also be broken down by many proteolytic enzymes to its constituent amino acids. Because of these breakdown systems, the turnover of insulin in the body is rapid; its “half-life” has been estimated to be 10–30 min. The liver alone is capable of destroying about 50% of the insulin passing through it on its way from the pancreas to the bodily tissues.

The role played by insulin in the body is most clearly approached by considering the abnormalities resulting from removing insulin from an organism by surgical excision of the pancreas or by the chemical destruction of the insulin-producing cells: A state of severe diabetes is produced. Normally the blood glucose level is about 100 mg/100 ml. A carbohydrate meal raises the blood sugar to about 150 mg and the premeal value is reached again within 1.5 h. The normal organism manages to dispose of food by storage and oxidation within this period because insulin is present. When food (carbohydrate and protein) reaches the upper intestine, a substance is liberated which in turn stimulates the beta cells to secrete extra insulin. Insulin acts on most tissues to speed the uptake of glucose. In the cells the glucose is burned for energy, stored as glycogen, or transformed to and stored as fat. The human pancreas probably produces 1–2 mg of the hormone per day. This is sufficient to regulate the metabolism of more than 250 g of carbohydrate, 70 g of protein, and 75 g of fat, the usual composition of an ordinary 2000-calorie diet.

In diabetes the rate of glucose uptake is slowed, the level of circulating blood sugar rises, and sugar spills over into the excreted urine. Calories are wasted, more water is excreted, and there is muscular weakness and weight loss; hence urinary frequency, hunger, thirst, and fatigue. Whenever glucose metabolism is defective, stored fat is broken down to fatty acids because of the actions of adrenaline and the pituitary growth hormone. Insulin is able to reverse all these phenomena by favoring storage and swift intake of glucose into the tissues, by decreasing the breakdown of stored fat, and by promoting protein synthesis. See also Diabetes.

When insulin is secreted or given in excess, it may lower the blood sugar level much below its normal value, causing hypoglycemia. Hypoglycemia is dangerous because the metabolism in the brain cells depends primarily upon an adequate supply of glucose.

The precise molecular mechanisms of insulin action are still not known. The initial step is the binding of the hormone to a specific receptor on the cell membrane. This event somehow activates a set of transport molecules, so that glucose, potassium, and amino acids enter cells more freely. At the same time, fat breakdown is slowed and glycogen storage increased. All these actions depend upon the integrity of the outer cell membrane. See also Cell permeability.

Not all the cells of the body require or respond to insulin. The insulin-responsive tissues are the liver, skeletal muscle, the heart, and the adipose tissue. Sensitivity to insulin is affected by many conditions. Obesity, antibodies to the hormone or its receptor, oversecretion of growth hormone or adrenal steroids, ketosis, and unknown genetic factors all cause insulin resistance. Muscular exercise, correction of obesity, and a deficiency of pituitary or adrenal hormones are associated with an increased sensitivity to the hormone.


World of the Body: insulin
Top

Glucose, dissolved in the blood (blood sugar), is one of the main sources of energy for the body. Different organs and tissues use other fuels to varying extents, but the brain uses glucose exclusively. To protect vital functions mammals have evolved a mechanism for keeping the concentration of glucose in the blood fairly constant — an example of homeostasis. This includes diverse hormonal responses that increase the blood glucose concentration. Yet, in what seems a remarkable oversight of nature, the body relies almost entirely upon just one hormone, the protein insulin, to bring about a decrease in blood glucose. Insulin facilitates the entry of glucose from the blood into the tissues of the body.

It has been known since 1899 that removal of the pancreas from dogs led to diabetes, with its characteristic persistent increase in blood glucose (hyperglycaemia) and presence of sugar in the urine (glycosuria). The fascinating saga of the eventual discovery of insulin by Banting and Best in 1921 is well known. They were able to show that injection of an extract from the pancreas of a healthy dog led consistently to a decrease in the amount of sugar in the blood and urine of diabetic dogs. They published their account, entitled ‘The Internal Secretion of the Pancreas’, in 1922. Their experiments, which were to prove life-saving, assured the insulin molecule a key place in medical history, and won a Nobel Prize for Banting and Macleod (in whose Canadian laboratory the work was done) as well as earning the grateful thanks of diabetic people in their millions around the world. It was some 30 years later that Frederick Sanger embarked on his painstaking but highly successful molecular dissection of insulin, which unravelled its precise amino acid sequence. This was a landmark achievement, representing as it did the first successful sequencing of any protein molecule, and it earned Sanger his first Nobel Prize. With subsequent establishment of its three-dimensional structure, insulin was revealed as a vital protein of classic polypeptide design. Despite 300 million years of divergent evolution, the molecular form and function of insulin has been remarkably well conserved across the entire zoological spectrum.

The dynamic glucose-insulin system on which the body's metabolism so critically depends is controlled and modulated by various factors impinging on the ‘b-cells’, which are found in the pancreas in cellular nodules, the Islets of Langerhans — named after the German pathologist who described them in 1869, long before their function was known. These ‘b-cells’ detect glucose in the blood and secrete insulin in appropriate amounts in response to the meal-induced tidal changes in blood glucose level.

Insulin is normally quite rapidly removed from the blood and survives in the circulation for only 5-15 min, thus placing a continuing demand on the b-cells for the release of more insulin in order to establish an effective feedback control of blood glucose concentration. This moment-by-moment process requires, in the b-cells, mechanisms for the manufacture, storage, and rapid release of insulin. To replenish its insulin supply, the genes of a pancreatic b-cell switch on their protein manufacturing machinery, producing a much larger single chain precursor molecule, called pro-insulin, which contains the amino acid sequence of insulin. Successive and controlled proteolysis (breakdown of this protein molecule) finally leaves the 51 amino acid sequence of insulin itself, and ensures its correct folding to create the three-dimensional shape of the molecule. Once formed in the b-cell, insulin is stored in granules as a symmetrical hexagonal array of 6 insulin molecules combined in a stable crystalline structure with 2 atoms of zinc. When released into the circulation at effective concentrations, insulin is transported as, and normally acts as, a single molecule.

To exert its effects on target cells — muscle, liver, or fat cells — the insulin molecule must first be recognized by specific insulin-receptor protein molecules in the cell membranes. Part of the insulin receptor spans the membrane, so that, when an insulin molecule binds to the external part of the receptor, a signal is transmitted across the membrane to other molecules, leading to a cascade of enzyme activity in the target cells.

Insulin resistance may occur when the blood glucose level is not well controlled, as in a type of diabetes which begins in adult life, where the pancreatic b-cells do not produce enough insulin. Not only does this lead to the appearance of the symptoms of diabetes, but the high level of glucose in the blood decreases the sensitivity of the target cell receptors for insulin and so makes the situation worse. It is possible to treat this type of diabetes by mouth with agents that boost the output of insulin from any viable b-cells that are present, or reduce the blood sugar by other means. If, on the other hand, pancreatic b-cells have all been destroyed, as in juvenile diabetes, then insulin must be injected daily as replacement therapy.

Unfortunately insulin cannot be given orally because it is a peptide and is therefore rapidly broken down by enzymes in the gut. Different preparations of insulin are available for injection, depending on the duration of action required. Insulin was originally extracted on a massive scale from the pancreas of animals (cows or pigs). It can now be obtained by genetic engineering of bacterial cells, causing them to express human insulin. It is noteworthy that insulin was the first protein to be commercially produced by such recombinant technology. Although this allows large scale production and isolation, pig pancreas remains the main source of insulin for human treatment: pig insulin differs from human insulin by only one amino acid.

Various insulin formulations may combine rapid-, medium-, or long-acting forms of crystalline insulin so that individual requirements for insulin can be matched to blood glucose levels following meals. Insulin has thus become firmly established in modern medicine as a remarkably effective therapeutic agent, but a whole life-time of constant injection is an unwelcome hazard for anyone suffering from juvenile diabetes. The design and production of a non-peptide, orally-active insulin analogue therefore remains a major goal of pharmaceutical research.

— E. K. Matthews

See endocrine. See also blood sugar; hormones; metabolism; pancreas.

Food and Nutrition: insulin
Top

Hormone secreted by the β-cells of the pancreas which controls carbohydrate metabolism. Diabetes mellitus is the result of an inadequate supply of insulin or failure of its function. Since insulin is a protein it would be digested if taken by mouth so must be injected. See also diabetes; diet, diabetic; glucose tolerance.

Food and Fitness: insulin
Top

A hormone secreted by cells within the islets of Langerhans, in the pancreas. Insulin is released into the bloodstream in response to raised blood glucose levels. It stimulates the liver, muscles, and fat cells to remove glucose from the blood, and to store it as glycogen and fat in cells. It also promotes the conversion of glucose to fat and stimulates protein synthesis in muscles. Inhibition of insulin production (e.g. by adrenaline or exercise) results in increased blood glucose levels. Although insulin secretion is reduced during exercise, sensitivity to insulin increases in well-trained individuals. Lack of insulin or progressive loss of sensitivity to insulin, can result in diabetes mellitus.

Drug Info: Insulin, Inhaled
Top

Brand names: Exubera ®, Exubera®



Insulin inhalation powder

What is Insulin inhalation powder?

INSULIN INHALATION (Exubera®) is a human-made form of insulin. Insulin is a hormone produced naturally by the pancreas. Insulin lowers the amount of sugar in your blood. Keeping your blood sugar close to normal prevents or reduces long-term complications of diabetes including damage to the blood vessels, eyes, kidneys, or nerves. Insulin inhalation is a short-acting insulin that starts working faster than injected regular insulin. Because of the quicker onset of action, you should eat a meal within 10 minutes after inhaling your dose of insulin. This will help to reduce the risk of low blood sugar (hypoglycemia).The time-course of action of insulin may vary in different people and at different times in the same person. You need a prescription to buy inhaled insulin.

There are different types of insulin available. Each type has a different onset of action and a different duration of action in the body. You should learn which types you take and how you should administer them, and how each type acts in your body.

If you switch from injected insulin to inhaled insulin, your dose of insulin may change. Monitor your blood sugar more frequently. Take care to learn and recognize the symptoms of hypoglycemia (low blood sugar) and know how you should treat these reactions.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
• adrenal or pituitary gland problems
• asthma
• diarrhea
• fever or infection
• injury or trauma
• kidney disease
• liver disease
• lung diseases like COPD, chronic bronchitis, emphysema, or cystic fibrosis
• nausea, vomiting
• recent surgery
• thyroid disease
• currently smoke tobacco or quit smoking within the past 6 months
• an unusual reaction to Insulin, mannitol, medicines, foods, dyes, or preservatives
• pregnant or trying to get pregnant
• breast-feeding

How should this medicine be used?

This medicine is for inhalation by mouth. Use exactly as directed. Do not use more than prescribed. Do not use more or less often than prescribed. It is important to follow the directions given to you by your prescriber or health care professional. You will be taught how to use the inhaler. If you are using more than one blister pack for a dose, inhale each blister pack separately. If you use the 3 mg blister pack, and it becomes unavailable, do not substitute three 1 mg blister packs. Contact your health care provider for instructions.

Your health care provider will tell you how long to wait after you inhale your dose of insulin before eating a meal. Most of the time, you will wait for 10 minutes or less. You will also be taught how to adjust doses for activities and illness.

Clean the chamber and mouthpiece of the inhaler once a week with a damp cloth and mild soap. Rinse with warm water. Make sure the inhaler is fully dry before using it. For the base of the inhaler, wipe the outside with a damp soft cloth. Do not use soap or any other cleanser. Do not clean the Release Unit. It should be replaced every 2 weeks. The inhaler should be replaced once a year.

What drug(s) may interact with Insulin Inhalation?

• other medicines for diabetes
• other medicines that are inhaled, especially those used for asthma like albuterol

Many medications may cause changes (increase or decrease) in blood sugar, these include:
• alcohol containing beverages
• angiotensin converting enzyme inhibitors (ACE inhibitors), often used for high blood pressure or heart problems (examples include captopril, enalapril, lisinopril)
• antiretroviral protease inhibitors (examples include indinavir, ritonavir, saquinavir)
• aspirin and aspirin-like drugs
• beta-blockers, often used for high blood pressure or heart problems (examples include atenolol, metoprolol, propranolol)
• certain medicines used for mental depression, emotional, or psychotic disturbances
chromium
cisapride
clonidine
cyclosporine
danazol
diazoxide
disopyramide
epinephrine
• female hormones, such as estrogens, progestins, or contraceptive pills
fenofibrate
gemfibrozil
glucagon
• growth hormone (somatropin)
• guanethidine
• isoniazid
lithium
metoclopramide
• male hormones or anabolic steroids
• medications to suppress appetite or for weight loss
• medicines for allergies, asthma, cold, or cough
• niacin
• nicotine (including nicotine found in patches and gum)
pentamidine
pentoxifylline
phenytoin
propoxyphene
• quinolone antibiotics, medicines used for infections (examples include ciprofloxacin, levofloxacin, norfloxacin)
• some herbal dietary supplements
• steroid medicines such as prednisone or cortisone
• sulfonamides, medicines for infection ( examples include Azulfidine®, Bactrim®, Gantrisin® Septra®)
tacrolimus
• thyroid hormones
• water pills (diuretics)

Some medications can hide the warning symptoms of low blood sugar (hypoglycemia). You may need to monitor your blood sugar more closely if you are taking one of these medications. These include:
• beta-blockers, often used for high blood pressure or heart problems (examples include atenolol, metoprolol, propranolol)
clonidine
• guanethidine
reserpine

Tell your prescriber or health care professional about all other medicines you are taking, including non-prescription medicines, nutritional supplements, or herbal products. Also tell your prescriber or health care professional if you are a frequent user of drinks with caffeine or alcohol, if you smoke, or if you use illegal drugs. These may affect the way your medicine works. Check with your health care professional before stopping or starting any of your medicines.

What should I watch for while taking Insulin Inhalation?

Visit your health care professional or prescriber for regular checks on your progress. To control your diabetes properly you must use insulin regularly and follow a regular diet and exercise schedule. Diabetes cannot be cured. Careful, daily control of blood sugar can postpone or prevent many of the long-term complications of diabetes.

Treatment with inhaled insulin has caused small declines in lung function. Because of this effect, your doctor will monitor your lung function before and during treatment with Exubera®.

Dangerously high or low blood sugar can occur when meals and insulin are not spaced properly. Checking and recording your blood glucose and urine ketone levels regularly is important. Sometimes it is hard to tell the difference between low and high blood sugar (see side effects). Use a glucometer (blood glucose or sugar measuring device), whenever possible, before you treat high or low blood sugar.

Always carry a quick-source of sugar with you in case you have symptoms of low blood sugar (hypoglycemia). Examples include hard sugar candy or glucose tablets.

Do not switch brands or types of insulin without consulting your health care professional or prescriber. Switching insulin brand or type can cause dangerously high or low blood sugar.

Always keep an extra supply of insulin on hand.

Wear a Medic Alert bracelet or necklace and/or carry an identification card with your name and address, condition, medication, and prescriber's name and address.

If you develop a cold, diarrhea, vomiting, or other infection or illness, you should contact your health care professional or prescriber. 'Sick-days' may require changes to your insulin dosage. Or your illness may need to be evaluated. Ask your health care professional or prescriber what you should do if you become ill. Do not stop taking your insulin; check with your health care professional or prescriber for advice.

Many nonprescription cough and cold products contain sugar or alcohol. These can affect diabetes control or can alter the results of tests used to monitor blood sugar. Avoid alcohol. Avoid products that contain alcohol or sugar.

If you are going to have surgery, make sure you tell the health care professionals that you take insulin.

What side effects may I notice from receiving Insulin Inhalation?

Learn how and when you should monitor your blood sugar, and what you should do if high or low blood sugar occurs. Side effects that you should report to your prescriber or health care professional as soon as possible:

Symptoms of hypoglycemia (low blood glucose):
• anxiety or nervousness, confusion, difficulty concentrating, hunger, pale skin, nausea, fatigue, sweating, headache, palpitations, numbness of the mouth, tingling in the fingers, tremors, muscle weakness, blurred vision, cold sensations, uncontrolled yawning, irritability, rapid heartbeat, shallow breathing, and loss of consciousness. You should learn to recognize your own symptoms of hypoglycemia. Your symptoms may be different than others. If you are uncertain about your symptoms of hypoglycemia, check your blood sugar often to help you learn to recognize the symptoms. Hypoglycemia may cause you to not be aware of your actions or surroundings if it is severe, so you should let others know what to do if you cannot help yourself in a severe reaction. Your prescriber or health care professional will teach you how to treat hypoglycemia. Always carry a quick source of sugar such as candies or glucose tablets with you.

Symptoms of high blood sugar (hyperglycemia):
• dizziness, dry mouth, flushed dry-skin, fruit-like breath odor, loss of appetite, nausea, stomach ache, unusual thirst, frequent passing of urine

Insulin also can cause rare but serious allergic reactions in some patients, including:
• severe skin rash and itching (hives)
• difficulty breathing

Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome):
• cough
• bitter taste

Where can I keep my medicine?

Store the inhaled insulin blister packs at room temperature (15—30 degrees C or 59—86 degrees F). Once the foil overwrap is opened, use the blister packs within 3 months. Do not refrigerate or freeze the blister packs; throw away the blister packs if they freeze. Keep unused blister packs in the foil overwrap. Protect the blister packs from moisture; keep out of humid places like the bathroom. Store the inhaler and the release unit at room temperature.

Keep out of the reach of children in a container that small children cannot open.

Last updated: 10/20/2005 2:13:00 PM

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

A hormone secreted by the beta cells of the Islets of Langerhans in the pancreas in response to elevated blood glucose levels. Insulin stimulates the liver, muscles, and fat cells to remove glucose from the blood for use or storage; it stimulates liver cells to convert glucose to glycogen; it promotes the conversion of glucose to fats; and promotes glycolysis. Reduced insulin production or a decrease in the insulin-sensitivity of target cells causes blood glucose levels to increase. Insulin secretion is reduced by adrenergic impulses in the sympathetic nervous system, and by epinephrine (adrenaline). Insulin production falls during acute bouts of exercise, but insulin sensitivity of target cells increases. In trained individuals, insulin does not fall as much during exercise as in the untrained. This allows more energy to be derived from free fatty acids. Exogenous sources of insulin are in the World Doping Agency's 2005 Prohibited List.

 
insulin, hormone secreted by the β cells of the islets of Langerhans, specific groups of cells in the pancreas. Insufficiency of insulin in the body results in diabetes. Insulin was one of the first products to be manufactured using genetic engineering.

Action

In general, insulin acts to reduce extracellular (including blood plasma) levels of glucose by interacting in some way yet unknown with various cell membranes. In adipose (fatty) tissue it facilitates the cellular uptake of glucose and its subsequent conversion to fatty acids, and it inhibits the breakdown of fatty acids to simpler compounds. In muscle it again facilitates the transport of glucose into cells and in addition stimulates its conversion to glycogen. It also increases protein synthesis in muscle. In the liver, insulin facilitates glucose catabolism and its conversion to glycogen and inhibits its synthesis from simpler compounds.

Isolation and Structure

Canadians Frederick G. Banting and Charles H. Best were the first to obtain, from extracts of pancreas (1921-22), a preparation of insulin that could serve to replace a deficiency of the hormone in the human body. The complete amino acid sequence of the insulin molecule was described in the early 1950s; insulin was the first protein to be sequenced entirely. This pioneering work was confirmed from 1963 to 1966, when several groups reported laboratory synthesis of biologically active insulin. The three-dimensional structure of the crystalline hormone was published in 1969.

Insulin has been shown to be a protein consisting of two polypeptide chains (see peptide), one of 21 amino acid residues and the other of 30, joined by two disulfide bridges (see cysteine). The two chains are synthesized in the β cells as part of one continuous polypeptide chain called proinsulin; a 32-amino acid sequence (the connecting peptide) is subsequently split out of the proinsulin molecule by an enzyme resembling trypsin to yield active insulin.

Insulin in Diabetes Treatment

Many, but not all, of the symptoms of diabetes can be controlled by the administration of insulin. The forms of insulin available early in the 20th cent. had to be injected frequently because they were quick-acting. Later modifications gave the insulin solution a more prolonged action so that hypodermic injections could be made less frequently. Some now control their insulin levels via a small, portable insulin pump. In certain cases of mild diabetes, oral medications that stimulate production of insulin can be taken in lieu of insulin. See glucagon.


Health Dictionary: insulin
Top
(in-suh-lin, in-syuh-lin)

A hormone secreted by the pancreas that regulates the levels of sugar in the blood.

  • Persons suffering from diabetes mellitus may receive periodic or daily injections of insulin as a treatment for the disease.

  • A double-chain peptide hormone formed from proinsulin in the beta cells of the pancreatic islets of Langerhans. Insulin promotes the storage of glucose and the uptake of amino acids, increases protein and lipid synthesis, and inhibits lipolysis and gluconeogenesis.
    The secretion of endogenous insulin is a response of the beta cells to a stimulus. The primary stimulus is glucose; others are amino acids, particularly leucine, and the ‘gut hormones’, such as secretin, pancreozymin and gastrin. These chemicals play an important role in maintaining normal blood glucose levels by triggering the release of insulin after ingestion of a meal.
    Commercially prepared insulin is available in various types, which differ in the speed with which they act and in the duration of their effectiveness. There are three main groups: rapid acting (regular or semilente), intermediate acting (isophane suspension or NPH, zinc suspension or lente), and long acting (protamine zinc suspension or PZI, or ultralente). Mixtures are also marketed.

    • i. deficiency — diabetes mellitus.
    • i.-dextrose therapy — a combination used in emergencies to lower blood potassium levels in acute hypoadrenocorticism.
    • i.:glucagon ratio — ratio of insulin to glucagon; thought to determine the predominance of the action of one hormone over the other.
    • i.:glucose ratio — a comparison of simultaneously obtained blood levels of immunoreactive insulin and plasma glucose. An increased ratio suggests an insulin-secreting tumor of the pancreas. A modification is the amended insulin:glucose ratio, based on the calculation:
    • — $$\vskip13.5pt{\rm {serum\ insulin (\rmmu U/ml)\times100} \over {\rm plasma \ glucose (mg/dl) - 30}$$
    • immunoreactive i. — radioimmunoassay methods are used in determining blood levels of insulin. Increased levels are found with hypoglycemia caused by functional islet cell tumors.
    • i. pump — a device consisting of a syringe filled with a predetermined amount of short-acting insulin, a plastic cannula and a needle, and a pump that periodically delivers the desired amount of insulin. Sometimes used in humans, but of limited application in animals.
    • i. sensitivity test, i. response test — used to differentiate diabetes mellitus from pituitary and adrenal diabetes. A test dose of exogenous insulin will produce a rapid and marked decrease in blood glucose if the pancreas is not secreting sufficient insulin. A much less dramatic response is produced if hyperglycemia is due to excessive secretion of either pituitary or adrenocortical hormones rather than insufficient insulin production.
    • i. syringe — disposable syringe with a capacity of 1 ml or less and a fine gauge needle (27–29G) attached, and graduation markings corresponding to insulin units in standard preparations. Needles may also be treated to minimize pain on injection.
    Wikipedia: Insulin
    Top
    edit
    Insulin
    InsulinHexamer.jpg
    Computer-generated image of six insulin molecules assembled in a hexamer, highlighting the threefold symmetry, the zinc ions holding it together, and the histidine residues involved in zinc binding. Insulin is stored in the body as a hexamer, while the active form is the monomer. [1]
    Available structures
    1ai0, 1aiy, 1aph, 1b17, 1b18, 1b19, 1b2a, 1b2b, 1b2c, 1b2d, 1b2e, 1b2f, 1b2g, 1b9e, 1ben, 1bph, 1cph, 1dph, 1ev3, 1ev6, 1evr, 1fu2, 1fub, 1g7a, 1g7b, 1guj, 1hiq, 1hit, 1hls, 1htv, 1iza, 1izb, 1j73, 1jca, 1jco, 1lph, 1m5a, 1mhi, 1mhj, 1mpj, 1mso, 1os3, 1os4, 1q4v, 1qiy, 1qiz, 1qj0, 1rwe, 1sf1, 1t0c, 1trz, 1tyl, 1tym, 1uz9, 1w8p, 1wav, 1xda, 1xgl, 1xw7, 1zeg, 1zeh, 1zni, 1znj, 2a3g, 2aiy, 2bn1, 2bn3, 2c8q, 2c8r, 2g4m, 2g54, 2g56, 2hiu, 2ins, 2omg, 2omh, 2omi, 2tci, 3aiy, 3ins, 3mth, 4aiy, 4ins, 5aiy, 6ins, 7ins, 9ins
    Identifiers
    Symbols INS;
    External IDs OMIM176730 MGI96573 HomoloGene173
    RNA expression pattern
    PBB GE INS 206598 at tn.png
    More reference expression data
    Orthologs
    Species Human Mouse
    Entrez 3630 16334
    Ensembl ENSG00000129965 ENSMUSG00000000215
    UniProt P01308 Q5EEX1
    RefSeq NM_000207 (mRNA) NM_008387 (mRNA)
    NP_000198 (protein) NP_032413 (protein)
    Location Chr 11:
    2.14 - 2.14 Mb
    Chr 7:
    142.49 - 142.49 Mb
    PubMed search [1] [2]
    The idealised diagram shows the fluctuation of blood sugar (red) and the sugar-lowering hormone insulin (blue) in humans during the course of a day containing three meals. In addition, the effect of a sugar-rich versus a starch-rich meal is highlighted.

    Insulin is a hormone that has extensive effects on metabolism and other body functions, such as vascular compliance. Insulin causes cells in the liver, muscle, and fat tissue to take up glucose from the blood, storing it as glycogen in the liver and muscle, and stopping use of fat as an energy source. When insulin is absent (or low), glucose is not taken up by body cells, and the body begins to use fat as an energy source, for example, by transfer of lipids from adipose tissue to the liver for mobilization as an energy source. As its level is a central metabolic control mechanism, its status is also used as a control signal to other body systems (such as amino acid uptake by body cells). It has several other anabolic effects throughout the body. When control of insulin levels fails, diabetes mellitus will result.

    Insulin is used medically to treat some forms of diabetes mellitus. Patients with Type 1 diabetes mellitus depend on external insulin (most commonly injected subcutaneously) for their survival because the hormone is no longer produced internally. Patients with Type 2 diabetes mellitus are insulin resistant, and because of such resistance, may suffer from a relative insulin deficiency. Some patients with Type 2 diabetes may eventually require insulin when other medications fail to control blood glucose levels adequately.

    Insulin is a peptide hormone composed of 51 amino acids and has a molecular weight of 5808 Da. It is produced in the islets of Langerhans in the pancreas. The name comes from the Latin insula for "island".

    Insulin's structure varies slightly between species of animal. Insulin from animal sources differs somewhat in 'strength' (in carbohydrate metabolism control effects) in humans because of those variations. Porcine (pig) insulin is especially close to the human version.

    Contents

    Gene

    The proinsulin precursor of insulin is encoded by the INS gene.[2][3]

    Alleles

    A variety of mutant alleles with changes in the coding region have been identified. There is a read-through gene, INS-IGF2, which overlaps with this gene at the 5' region and with the IGF2 gene at the 3' region.[2]

    Regulation

    There are several regulatory sequences in the promoter region of the human insulin gene, to which transcription factors bind.

    In general, the A-boxes bind to Pdx1 factors, E-boxes bind to NeuroD, C-boxes bind to MafA and cAMP response elements to CREB.

    There are also silencers that inhibit transcription.

    Regulatory sequences and their transcription factors for the insulin gene.[4]
    Regulatory sequence binding transcription factors
    ILPR Par1
    A5 Pdx1
    negative regulatory element (NRE)[5] glucocorticoid receptor, Oct1
    Z (overlapping NRE and C2) ISF
    C2 Pax4, MafA(?)
    E2 USF1/USF2
    A3 Pdx1
    CREB RE -
    CREB RE CREB, CREM
    A2 -
    CAAT enhancer binding (CEB) (partly overlapping A2 and C1) -
    C1 -
    E1 E2A, NeuroD1, HEB
    A1 Pdx1
    G1 -

    Protein structure

    Within vertebrates, the similarity of insulins is extremely close. Bovine insulin differs from human in only three amino acid residues, and porcine insulin in one. Even insulin from some species of fish is similar enough to human to be clinically effective in humans. Insulin in some invertebrates (eg, the Caenorhabditis elegans nematode) is quite close to human insulin, has similar effects inside cells, and is produced very similarly. Insulin has been strongly preserved over evolutionary time, suggesting its centrality in animal metabolic control. The C-peptide of proinsulin (discussed later), however, differs much more amongst species; it is also a hormone, but a secondary one.

    Insulin is produced and stored in the body as a hexamer (a unit of six insulin molecules), while the active form is the monomer. The hexamer is an inactive form with long-term stability which serves as a way to keep the highly reactive insulin protected, yet readily available. The hexamer-monomer conversion is one of the central aspects of insulin formulations for injection. The hexamer is far more stable than the monomer, which is desirable for practical reasons, however the monomer is a much faster reacting drug because diffusion rate is inversely related to particle size. A fast reacting drug means that insulin injections do not have to precede mealtimes by hours, which in turn gives diabetics more flexibility in their daily schedule.[6] Insulin can aggregate and form fibrillar interdigitated beta-sheets. This can cause injection amyloidosis, and prevents the storage of insulin for long periods.[7]

    Synthesis, physiological effects, and degradation

    Synthesis

    Insulin is produced in the pancreas and released when any of the several stimuli is detected. The stimuli include ingested protein and glucose in the blood produced from digested food. Carbohydrate produces glucose, although not all types of carbohydrate produce glucose and thereby increase blood glucose levels. In target cells, they initiate a signal transduction, which has the effect of increasing glucose uptake and storage. Finally, insulin is degraded, terminating the response.

    Insulin undergoes extensive posttranslational modification along the production pathway. Production and secretion are largely independent; prepared insulin is stored awaiting secretion. Both C-peptide and mature insulin are biologically active. Cell components and proteins in this image are not to scale.

    In mammals, insulin is synthesized in the pancreas within the beta cells (β-cells) of the islets of Langerhans. One million to three million islets of Langerhans (pancreatic islets) form the endocrine part of the pancreas, which is primarily an exocrine gland. The endocrine portion only accounts for 2% of the total mass of the pancreas. Within the islets of Langerhans, beta cells constitute 60–80% of all the cells.

    In beta cells, insulin is synthesized from the proinsulin precursor molecule by the action of proteolytic enzymes, known as prohormone convertases (PC1 and PC2), as well as the exoprotease carboxypeptidase E.[8] These modifications of proinsulin remove the center portion of the molecule (ie, C-peptide), from the C- and N- terminal ends of proinsulin. The remaining polypeptides (51 amino acids in total), the B- and A- chains, are bound together by disulfide bonds/disulphide bonds. Confusingly, the primary sequence of proinsulin goes in the order "B-C-A", since B and A chains were identified on the basis of mass, and the C peptide was discovered after the others.

    The endogenous production of insulin is regulated in several steps along the synthesis pathway:

    It has been shown that insulin and its related proteins, are also produced inside the brain and that reduced levels of these proteins are linked to Alzheimer's disease.[9][10][11]

    Release

    Beta cells in the islets of Langerhans release insulin in two phases. The first phase insulin release is rapidly triggered in response to increased blood glucose levels. The second phase is a sustained, slow release of newly formed vesicles that are triggered independently of sugar. The description of first phase release is as follows:

    This is the main mechanism for release of insulin. In addition some insulin release takes place generally with food intake, not just glucose or carbohydrate intake, and the beta cells are also somewhat influenced by the autonomic nervous system. The signaling mechanisms controlling these linkages are not fully understood.

    Other substances known to stimulate insulin release include amino acids from ingested proteins, acetylcholine, released from vagus nerve endings (parasympathetic nervous system), cholecystokinin[citation needed], released by enteroendocrine cells of intestinal mucosa and glucose-dependent insulinotropic peptide (GIP). Three amino acids (alanine, glycine and arginine) act similarly to glucose by altering the beta cell's membrane potential. Acetylcholine triggers insulin release through phospholipase C, while the last acts through the mechanism of adenylate cyclase.

    The sympathetic nervous system (via Alpha2-adrenergic stimulation as demonstrated by the agonists clonidine or methyldopa) inhibit the release of insulin. However, it is worth noting that circulating adrenaline will activate Beta2-Receptors on the Beta cells in the pancreatic Islets to promote insulin release. This is important since muscle cannot benefit from the raised blood sugar resulting from adrenergic stimulation (increased gluconeogenesis and glycogenolysis from the low blood insulin: glucagon state) unless insulin is present to allow for GLUT-4 translocation in the tissue. Therefore, beginning with direct innervation, norepinephrine inhibits insulin release via alpha2-receptors, then subsequently, circulating adrenaline from the adrenal medulla will stimulate beta2-receptors thereby promoting insulin release.

    When the glucose level comes down to the usual physiologic value, insulin release from the beta cells slows or stops. If blood glucose levels drop lower than this, especially to dangerously low levels, release of hyperglycemic hormones (most prominently glucagon from Islet of Langerhans' alpha cells) forces release of glucose into the blood from cellular stores, primarily liver cell stores of glycogen. By increasing blood glucose, the hyperglycemic hormones prevent or correct life-threatening hypoglycemia. Release of insulin is strongly inhibited by the stress hormone norepinephrine (noradrenaline), which leads to increased blood glucose levels during stress.

    Evidence of impaired first phase insulin release can be seen in the glucose tolerance test, demonstrated by a substantially elevated blood glucose level at 30 minutes, a marked drop by 60 minutes, and a steady climb back to baseline levels over the following hourly time points.

    Oscillations

    Insulin release from pancreas oscillates with a period of 3–6 minutes.[12]

    Even during digestion, generally one or two hours following a meal, insulin release from pancreas is not continuous, but oscillates with a period of 3–6 minutes, changing from generating a blood insulin concentration more than ~800 pmol/l to less than 100 pmol/l.[12] This is thought to avoid downregulation of insulin receptors in target cells and to assist the liver in extracting insulin from the blood.[12] This oscillation is important to consider when administering insulin-stimulating medication, since it is the oscillating blood concentration of insulin release which should, ideally, be achieved, not a constant high concentration.[12] It is also important to consider in that all methods of insulin replacement can never hope to replicate this delivery mechanism precisely. This may be achieved by delivering insulin rhythmically to the portal vein or by islet cell transplantation to the liver.[12] Future insulin pumps hope to address this characteristic. (See also Pulsatile Insulin.)

    Signal transduction

    There are special transporter proteins in cell membranes through which glucose from the blood can enter a cell. These transporters are, indirectly, under blood insulin's control in certain body cell types (e.g., muscle cells). Low levels of circulating insulin, or its absence, will prevent glucose from entering those cells (e.g., in Type 1 diabetes). However, more commonly there is a decrease in the sensitivity of cells to insulin (e.g., the reduced insulin sensitivity characteristic of Type 2 diabetes), resulting in decreased glucose absorption. In either case, there is 'cell starvation', weight loss, sometimes extreme. In a few cases, there is a defect in the release of insulin from the pancreas. Either way, the effect is, characteristically, the same: elevated blood glucose levels.

    Activation of insulin receptors leads to internal cellular mechanisms that directly affect glucose uptake by regulating the number and operation of protein molecules in the cell membrane that transport glucose into the cell. The genes that specify the proteins that make up the insulin receptor in cell membranes have been identified and the structure of the interior, cell membrane section, and now, finally after more than a decade, the extra-membrane structure of receptor (Australian researchers announced the work 2Q 2006).

    Two types of tissues are most strongly influenced by insulin, as far as the stimulation of glucose uptake is concerned: muscle cells (myocytes) and fat cells (adipocytes). The former are important because of their central role in movement, breathing, circulation, etc, and the latter because they accumulate excess food energy against future needs. Together, they account for about two-thirds of all cells in a typical human body.

    Physiological effects

    Effect of insulin on glucose uptake and metabolism. Insulin binds to its receptor (1) which in turn starts many protein activation cascades (2). These include: translocation of Glut-4 transporter to the plasma membrane and influx of glucose (3), glycogen synthesis (4), glycolysis (5) and fatty acid synthesis (6).

    The actions of insulin on the global human metabolism level include:

    • Control of cellular intake of certain substances, most prominently glucose in muscle and adipose tissue (about ⅔ of body cells).
    • Increase of DNA replication and protein synthesis via control of amino acid uptake.
    • Modification of the activity of numerous enzymes.

    The actions of insulin on cells include:

    • Increased glycogen synthesis – insulin forces storage of glucose in liver (and muscle) cells in the form of glycogen; lowered levels of insulin cause liver cells to convert glycogen to glucose and excrete it into the blood. This is the clinical action of insulin which is directly useful in reducing high blood glucose levels as in diabetes.
    • Increased fatty acid synthesis – insulin forces fat cells to take in blood lipids which are converted to triglycerides; lack of insulin causes the reverse.
    • Increased esterification of fatty acids – forces adipose tissue to make fats (i.e., triglycerides) from fatty acid esters; lack of insulin causes the reverse.
    • Decreased proteolysis – decreasing the breakdown of protein.
    • Decreased lipolysis – forces reduction in conversion of fat cell lipid stores into blood fatty acids; lack of insulin causes the reverse.
    • Decreased gluconeogenesis – decreases production of glucose from non-sugar substrates, primarily in the liver (remember, the vast majority of endogenous insulin arriving at the liver never leaves the liver); lack of insulin causes glucose production from assorted substrates in the liver and elsewhere.
    • Decreased autophagy - decreased level of degradation of damaged organelles. Postprandial levels inhibit autophagy completely.[13]
    • Increased amino acid uptake – forces cells to absorb circulating amino acids; lack of insulin inhibits absorption.
    • Increased potassium uptake – forces cells to absorb serum potassium; lack of insulin inhibits absorption. Thus lowers potassium levels in blood.
    • Arterial muscle tone – forces arterial wall muscle to relax, increasing blood flow, especially in micro arteries; lack of insulin reduces flow by allowing these muscles to contract.
    • Increase in the secretion of hydrochloric acid by Parietal cells in the stomach.

    Degradation

    Once an insulin molecule has docked onto the receptor and effected its action, it may be released back into the extracellular environment, or it may be degraded by the cell. Degradation normally involves endocytosis of the insulin-receptor complex followed by the action of insulin degrading enzyme. Most insulin molecules are degraded by liver cells. It has been estimated that an insulin molecule produced endogenously by the pancreatic beta cells is degraded within approximately one hour after its initial release into circulation (insulin half-life ~ 4–6 minutes).[14]

    Hypoglycemia

    Although other cells can use other fuels for a while (most prominently fatty acids), neurons depend on glucose as a source of energy in the non-starving human. They do not require insulin to absorb glucose, unlike muscle and adipose tissue, and they have very small internal stores of glycogen. Glycogen stored in liver cells (unlike glycogen stored in muscle cells) can be converted to glucose, and released into the blood, when glucose from digestion is low or absent, and the glycerol backbone in triglycerides can also be used to produce blood glucose.

    Sufficient lack of glucose and scarcity of these sources of glucose can dramatically make itself manifest in the impaired functioning of the central nervous system; dizziness, speech problems, and even loss of consciousness, can occur. Low glucose is known as hypoglycemia or, in cases producing unconsciousness, "hypoglycemic coma" (sometimes termed "insulin shock" from the most common causative agent). Endogenous causes of insulin excess (such as an insulinoma) are very rare, and the overwhelming majority of insulin-excess induced hypoglycemia cases are iatrogenic and usually accidental. There have been a few reported cases of murder, attempted murder, or suicide using insulin overdoses, but most insulin shocks appear to be due to errors in dosage of insulin (e.g., 20 units of insulin instead of 2) or other unanticipated factors (didn't eat as much as anticipated, or exercised more than expected, or unpredicted kinetics of the subcutaneously injected insulin itself).

    Possible causes of hypoglycemia include:

    • External insulin (usually injected subcutaneously).
    • Oral hypoglycemic agents (e.g., any of the sulfonylureas, or similar drugs, which increase insulin release from beta cells in response to a particular blood glucose level).
    • Ingestion of low-carbohydrate sugar substitutes in people without diabetes or with type 2 diabetes. Animal studies show these can trigger insulin release, albeit in much smaller quantities than sugar, according to a report in Discover magazine, August 2004, p 18. (This can never be a cause of hypoglycemia in patients with type 1 diabetes since there is no endogenous insulin production to stimulate.)

    Diseases and syndromes

    There are several conditions in which insulin disturbance is pathologic:

    • Diabetes mellitus – general term referring to all states characterized by hyperglycemia.
      • Type 1 – autoimmune-mediated destruction of insulin producing beta cells in the pancreas resulting in absolute insulin deficiency.
      • Type 2 – multifactoral syndrome with combined influence of genetic susceptibility and influence of environmental factors, the best known being obesity, age, and physical inactivity, resulting in insulin resistance in cells requiring insulin for glucose absorption. This form of diabetes is strongly inherited.
      • Other types of impaired glucose tolerance (see the diabetes article).
    • Insulinoma - a tumor of pancreatic beta cells producing excess of insulin or reactive hypoglycemia.
    • Metabolic syndrome – a poorly understood condition first called Syndrome X by Gerald Reaven, Reaven's Syndrome after Reaven, CHAOS in Australia (from the signs which seem to travel together), and sometimes prediabetes. It is currently not clear whether these signs have a single, treatable cause, or are the result of body changes leading to type 2 diabetes. It is characterized by elevated blood pressure, dyslipidemia (disturbances in blood cholesterol forms and other blood lipids), and increased waist circumference (at least in populations in much of the developed world). The basic underlying cause may be the insulin resistance of type 2 diabetes which is a diminished capacity for insulin response in some tissues (e.g., muscle, fat) to respond to insulin. Commonly, morbidities such as essential hypertension, obesity, Type 2 diabetes, and cardiovascular disease (CVD) develop.
    • Polycystic ovary syndrome – a complex syndrome in women in the reproductive years where there is anovulation and androgen excess commonly displayed as hirsutism. In many cases of PCOS insulin resistance is present.

    As a medication

    Biosynthetic "human" insulin is now manufactured for widespread clinical use using genetic engineering techniques using recombinant DNA technology. More recently, researchers have succeeded in introducing the gene for human insulin into plants and in producing insulin in plants, specifically safflower.[15][16] It is anticipated that this technique will reduce production costs.

    Several of these are slightly modified versions of human insulin which, while having a clinical effect on blood glucose levels as though they were exact copies, have been designed to have somewhat different absorption or duration of action characteristics. They are usually referred to as 'insulin analogues'. For instance, the first available, insulin lispro, does not exhibit a delayed absorption effect found in 'regular' insulin, and begins to have effect in as little as 15 minutes. Using it therefore does not require the pre-planning required for other insulins which begin to take effect much later (up to many hours) after administration. Another type is extended release insulin; the first of these was 'insulin glargine'. These have a steady effect for the entire time they are active, without the peak and drop of effect in other insulins; typically, they continue to have an insulin effect for an extended period from 18 to 24 hours.

    Unlike many medicines, insulin currently cannot be taken orally. Like nearly all other proteins introduced into the gastrointestinal tract, it is reduced to fragments (even single amino acid components), whereupon all 'insulin activity' is lost. There has been some research into ways to protect insulin from the digestive tract, so that it can be administered orally or sublingually. While experimental, several companies now have various formulations in human clinical trials, which if successful, could see commercialization in several years.

    Insulin is usually taken as subcutaneous injections by single-use syringes with needles, an insulin pump, or by repeated-use insulin pens with needles.

    History

    Discovery and characterization

    In 1869 Paul Langerhans, a medical student in Berlin, was studying the structure of the pancreas under a microscope when he identified some previously un-noticed tissue clumps scattered throughout the bulk of the pancreas. The function of the "little heaps of cells," later known as the Islets of Langerhans, was unknown, but Edouard Laguesse later suggested that they might produce secretions that play a regulatory role in digestion. Paul Langerhans' son, Archibald, also helped to understand this regulatory role. The term insulin origins from Insel, the German word for islet/island.

    In 1889, the Polish-German physician Oscar Minkowski in collaboration with Joseph von Mering removed the pancreas from a healthy dog to test its assumed role in digestion. Several days after the dog's pancreas was removed, Minkowski's animal keeper noticed a swarm of flies feeding on the dog's urine. On testing the urine they found that there was sugar in the dog's urine, establishing for the first time a relationship between the pancreas and diabetes. In 1901, another major step was taken by Eugene Opie, when he clearly established the link between the Islets of Langerhans and diabetes: Diabetes mellitus … is caused by destruction of the islets of Langerhans and occurs only when these bodies are in part or wholly destroyed. Before his work, the link between the pancreas and diabetes was clear, but not the specific role of the islets.

    The structure of insulin. The left side is a space-filling model of the insulin monomer, believed to be biologically active. Carbon is green, hydrogen white, oxygen red, and nitrogen blue. On the right side is a cartoon of the insulin hexamer, believed to be the stored form. A monomer unit is highlighted with the A chain in blue and the B chain in cyan. Yellow denotes disulfide bonds, and magenta spheres are zinc ions.

    Over the next two decades, several attempts were made to isolate whatever it was the islets produced as a potential treatment. In 1906 George Ludwig Zuelzer was partially successful treating dogs with pancreatic extract but was unable to continue his work. Between 1911 and 1912, E.L. Scott at the University of Chicago used aqueous pancreatic extracts and noted a slight diminution of glycosuria but was unable to convince his director of his work's value; it was shut down. Israel Kleiner demonstrated similar effects at Rockefeller University in 1919, but his work was interrupted by World War I and he did not return to it.

    Nicolae Paulescu, a professor of physiology at the University of Medicine and Pharmacy in Bucharest, was the first one to isolate insulin, which he called at that time pancrein, and published in 1921 the work that he had carried out in Bucharest. Use of his techniques was patented in Romania, though no clinical use resulted.[17]

    In October 1920 Canadian Frederick Banting was reading one of Minkowski's papers and concluded that it is the very digestive secretions that Minkowski had originally studied that were breaking down the islet secretion(s), thereby making it impossible to extract successfully. He jotted a note to himself Ligate pancreatic ducts of the dog. Keep dogs alive till acini degenerate leaving islets. Try to isolate internal secretion of these and relieve glycosurea.

    The idea was that the pancreas's internal secretion, which supposedly regulates sugar in the bloodstream, might hold the key to the treatment of diabetes. A surgeon by training, Banting knew that certain arteries could be tied off that would lead to atrophy of most of the pancreas while leaving the islets of Langerhans intact. He theorized that a relatively pure extract could be made from the islets once most of the rest of pancreas was gone.

    In the Spring of 1921 Banting traveled to Toronto to explain his idea to J.J.R. Macleod who was Professor of Physiology at the University of Toronto, and asked Macleod if he could use his lab space to test the idea. Macleod was initially skeptical, but eventually agreed to let Banting use his lab space while he was on vacation for the summer. He also supplied Banting with ten dogs to experiment on, and two medical students, Charles Best and Clark Noble, to use as lab assistants, before leaving for Scotland. Since Banting only required one lab assistant, Best and Noble flipped a coin to see which would assist Banting for the first half of the summer. Best won the coin toss, and took the first shift as Banting's assistant. Loss of the coin toss may have proved unfortunate for Noble, given that Banting decided to keep Best for the entire summer, and eventually shared half his Nobel Prize money and a large part of the credit for the discovery of insulin with the winner of the toss. Had Noble won the toss, his career might have taken a different path.[18] Banting's method was to tie a ligature (string) around the pancreatic duct, and, when examined several weeks later, the pancreatic digestive cells had died and been absorbed by the immune system, leaving thousands of islets. They then isolated an extract from these islets, producing what they called isletin (what we now know as insulin), and tested this extract on the dogs. Banting and Best were then able to keep a pancreatectomized dog named Alpha alive for the rest of the summer by injecting her with the crude extract they had prepared. Removal of the pancreas in test animals essentially mimics diabetes, leading to elevated blood glucose levels. Alpha was able to remain alive because the extracts, containing isletin, were able to lower her blood glucose levels.

    Banting and Best presented their results to Macleod on his return to Toronto in the fall of 1921, but Macleod pointed out flaws with the experimental design, and suggested the experiments be repeated with more dogs and better equipment. He then supplied Banting and Best with a better laboratory, and began paying Banting a salary from his research grants. Several weeks later, it was clear the second round of experiments was also a success; and Macleod helped publish their results privately in Toronto that November. However, they needed six weeks to extract the isletin, which forced considerable delays. Banting suggested that they try to use fetal calf pancreas, which had not yet developed digestive glands; he was relieved to find that this method worked well. With the supply problem solved, the next major effort was to purify the extract. In December 1921, Macleod invited the biochemist James Collip to help with this task, and, within a month, the team felt ready for a clinical test.

    On January 11, 1922, Leonard Thompson, a 14-year-old diabetic who lay dying at the Toronto General Hospital, was given the first injection of insulin. However, the extract was so impure that Thompson suffered a severe allergic reaction, and further injections were canceled. Over the next 12 days, Collip worked day and night to improve the ox-pancreas extract, and a second dose was injected on the 23rd. This was completely successful, not only in having no obvious side-effects, but in completely eliminating the glycosuria sign of diabetes.

    Children dying from diabetic keto-acidosis were kept in large wards, often with 50 or more patients in a ward, mostly comatose. Grieving family members were often in attendance, awaiting the (until then, inevitable) death. In one of medicine's more dramatic moments Banting, Best, and Collip went from bed to bed, injecting an entire ward with the new purified extract. Before they had reached the last dying child, the first few were awakening from their coma, to the joyous exclamations of their families.[citation needed]

    However, Banting and Best never worked well with Collip, regarding him as something of an interloper, and Collip left the project soon after.

    Over the spring of 1922, Best managed to improve his techniques to the point where large quantities of insulin could be extracted on demand, but the preparation remained impure. The drug firm Eli Lilly and Company had offered assistance not long after the first publications in 1921, and they took Lilly up on the offer in April. In November, Lilly made a major breakthrough and were able to produce large quantities of highly refined, 'pure' insulin. Insulin was offered for sale shortly thereafter.

    Purified animal-sourced insulin was the only type of insulin available to diabetics until genetic breakthroughs occurred later with medical research. The amino-acid structure of insulin was characterized in the 1950s and the first synthetic insulin was produced simultaneously in the labs of Panayotis Katsoyannis at the University of Pittsburgh and Helmut Zahn at RWTH Aachen University in the early 1960s.[19][20]

    The first genetically-engineered, synthetic "human" insulin was produced in a laboratory in 1977 by Herbert Boyer using E. coli.[21][22] Partnering with Genentech founded by Boyer, Eli Lilly went on in 1982 to sell the first commercially available biosynthetic human insulin under the brand name Humulin.[22] The vast majority of insulin currently used worldwide is now biosynthetic recombinant "human" insulin or its analogs.

    Nobel prizes

    The Nobel Prize committee in 1923 credited the practical extraction of insulin to a team at the University of Toronto and awarded the Nobel Prize to two men; Frederick Banting and J.J.R. Macleod. They were awarded the Nobel Prize in Physiology or Medicine in 1923 for the discovery of insulin. Banting, insulted that Best was not mentioned, shared his prize with Best, and Macleod immediately shared his with James Collip. The patent for insulin was sold to the University of Toronto for one dollar.

    Surprisingly, while Paulescu's pioneering work was being completely ignored by the Nobel prize committee, Professor Ian Murray was particularly active in working to correct the historical wrong against Paulescu. Murray was a professor of physiology at the Anderson College of Medicine in Glasgow, Scotland, the head of the department of Metabolic Diseases at a leading Glasgow hospital, vice-president of the British Association of Diabetes, and a founding member of the International Diabetes Federation. In an article for a 1971 issue of the Journal of the History of Medicine and Allied Sciences, Murray wrote:

    "Insufficient recognition has been given to Paulesco, the distinguished Roumanian scientist, who at the time when the Toronto team were commencing their research had already succeeded in extracting the antidiabetic hormone of the pancreas and proving its efficacy in reducing the hyperglycaemia in diabetic dogs."

    Furthermore, Murray reported:

    "In a recent private communication Professor Tiselius, head of the Nobel Institute, has expressed his personal opinion that Paulesco was equally worthy of the award in 1923."[17]

    The primary structure of insulin was determined by British molecular biologist Frederick Sanger. It was the first protein to have its sequence be determined. He was awarded the 1958 Nobel Prize in Chemistry for this work.

    In 1969, after decades of work, Dorothy Crowfoot Hodgkin determined the spatial conformation of the molecule, the so-called tertiary structure, by means of X-ray diffraction studies. She had been awarded a Nobel Prize in Chemistry in 1964 for the development of crystallography.

    Rosalyn Sussman Yalow received the 1977 Nobel Prize in Medicine for the development of the radioimmunoassay for insulin.

    See also

    References

    1. ^ PDB 1ai0; Chang X, Jorgensen AM, Bardrum P, Led JJ (August 1997). "Solution structures of the R6 human insulin hexamer,". Biochemistry 36 (31): 9409–22. doi:10.1021/bi9631069. PMID 9235985. 
    2. ^ a b "Entrez Gene: INS insulin". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3630. 
    3. ^ Bell GI, Pictet RL, Rutter WJ, Cordell B, Tischer E, Goodman HM (March 1980). "Sequence of the human insulin gene". Nature 284 (5751): 26–32. doi:10.1038/284026a0. PMID 6243748. 
    4. ^ Melloul D, Marshak S, Cerasi E (2002). "Regulation of insulin gene transcription". Diabetologia 45 (3): 309–26. doi:10.1007/s00125-001-0728-y. PMID 11914736. 
    5. ^ Jang WG, Kim EJ, Park KG, Park YB, Choi HS, Kim HJ, Kim YD, Kim KS, Lee KU, Lee IK (2007). "Glucocorticoid receptor mediated repression of human insulin gene expression is regulated by PGC-1alpha". Biochem. Biophys. Res. Commun. 352 (3): 716–21. doi:10.1016/j.bbrc.2006.11.074. PMID 17150186. 
    6. ^ Dunn MF (August 2005). "Zinc-ligand interactions modulate assembly and stability of the insulin hexamer -- a review". Biometals 18 (4): 295–303. doi:10.1007/s10534-005-3685-y. PMID 16158220. 
    7. ^ Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D (November 2009). "Molecular basis for insulin fibril assembly". Proc. Natl. Acad. Sci. U.S.A. 106 (45): 18990–5. doi:10.1073/pnas.0910080106. PMID 19864624. 
    8. ^ Steiner DF, Oyer PE (February 1967). "The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma". Proc. Natl. Acad. Sci. U.S.A. 57 (2): 473–480. doi:10.1073/pnas.57.2.473. PMID 16591494. 
    9. ^ de la Monte SM, Wands JR (February 2005). "Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease". J. Alzheimers Dis. 7 (1): 45–61. PMID 15750214. http://iospress.metapress.com/openurl.asp?genre=article&issn=1387-2877&volume=7&issue=1&spage=45. 
    10. ^ Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (February 2005). "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?". J. Alzheimers Dis. 7 (1): 63–80. PMID 15750215. http://iospress.metapress.com/openurl.asp?genre=article&issn=1387-2877&volume=7&issue=1&spage=63. 
    11. ^ a b c d e Hellman B, Gylfe E, Grapengiesser E, Dansk H, Salehi A (2007). "[Insulin oscillations--clinically important rhythm. Antidiabetics should increase the pulsative component of the insulin release]" (in Swedish). Lakartidningen 104 (32-33): 2236–9. PMID 17822201. 
    12. ^ Bergamini E, Cavallini G, Donati A, Gori Z (October 2007). "The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction". Ann. N. Y. Acad. Sci. 1114: 69–78. doi:10.1196/annals.1396.020. PMID 17934054. 
    13. ^ William C. Duckworth, Robert G. Bennett and Frederick G. Hamel (1998). "Insulin Degradation: Progress and Potential". Endocrine Reviews 19 (5): 608–624. doi:10.1210/er.19.5.608. PMID 9793760. http://edrv.endojournals.org/cgi/content/full/19/5/608#F1. 
    14. ^ From SemBiosys, A New Kind Of Insulin INSIDE WALL STREET By Gene G. Marcial(AUGUST 13, 2007)
    15. ^ http://www.i-sis.org.uk/gmSaffloweHumanPro-Insulin.php
    16. ^ a b Ian Murray (1971). "Paulesco and the Isolation of Insulin" (PDF). Journal of the History of Medicine and Allied Sciences 26 (2): 150–157. PMID 4930788. http://jhmas.oxfordjournals.org/cgi/reprint/XXVI/2/150.pdf. 
    17. ^ Wright JR (December 2002). "Almost famous: E. Clark Noble, the common thread in the discovery of insulin and vinblastine". CMAJ 167 (12): 1391–6. PMID 12473641. 
    18. ^ Goro, Fritz (1964-05-08). "First Man-made Protein in History". Life (New York, NY: Time, Inc.) 56 (19): 47. http://books.google.com/books?id=lkEEAAAAMBAJ&lpg=PA47&vq=insulin&pg=PA47#v=onepage&q=insulin&f=false. Retrieved 2009-11-02. 
    19. ^ Federwisch, Matthias; Dieken, Markus Leyck; De Meyts, Pierre, eds (2002). Insulin & Related Proteins – Structure to Function and Pharmacology. Dordrecht, Netherlands: Kluwer Academic Publishers. pp. ix. ISBN 1-4020-0655-1. http://books.google.com/books?id=Ula72_FSwy8C&lpg=PP11&dq=Panayotis%20Katsoyannis&lr=&as_drrb_is=q&as_minm_is=0&as_miny_is=&as_maxm_is=0&as_maxy_is=&as_brr=0&pg=PP11#v=onepage&q=Panayotis%20Katsoyannis&f=false. Retrieved 2009-11-02. 
    20. ^ "First Successful Laboratory Production of Human Insulin Announced". News Release. Genentech. 1978-09-06. http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=4160. Retrieved 2009-11-03. 
    21. ^ a b Tof I (1994). "Recombinant DNA technology in the synthesis of human insulin". Little Tree Publishing. http://www.littletree.com.au/dna.htm. Retrieved 2009-11-03. 

    Further reading

    • Reaven, Gerald M.; Ami Laws (ed.) (1999--04-15). Insulin Resistance: The Metabolic Syndrome X (1st ed.). Totowa, New Jersey: Humana Press. doi:10.1226/0896035883. ISBN 0-89603-588-3. 
    • Leahy, Jack L.; William T. Cefalu (ed.) (2002-03-22). Insulin Therapy (1st ed.). New York: Marcel Dekker. ISBN 0-8247-0711-7. 
    • Kumar, Sudhesh; Stephen O'Rahilly (ed.) (2005-01-14). Insulin Resistance: Insulin Action and Its Disturbances in Disease. Chichester, England: Wiley. ISBN 0-470-85008-6. 
    • Ehrlich, Ann; Carol L. Schroeder (2000-06-16). Medical Terminology for Health Professions (4th ed.). Thomson Delmar Learning. ISBN 0-7668-1297-9. 
    • Draznin, Boris; Derek LeRoith (September 1994). Molecular Biology of Diabetes: Autoimmunity and Genetics; Insulin Synthesis and Secretion. Totowa, New Jersey: Humana Press. doi:10.1226/0896032868. ISBN 0-89603-286-8. 
    • Famous Canadian Physicians: Sir Frederick Banting at Library and Archives Canada
    • McKeage K, Goa KL (2001). "Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus". Drugs 61 (11): 1599–624. doi:10.2165/00003495-200161110-00007. PMID 11577797. 

    External links


    Translations: Insulin
    Top

    Dansk (Danish)
    n. - insulin

    Nederlands (Dutch)
    insuline

    Français (French)
    n. - insuline

    Deutsch (German)
    n. - Insulin

    Ελληνική (Greek)
    n. - (βιολ.) ινσουλίνη

    Italiano (Italian)
    insulina

    Português (Portuguese)
    n. - insulina (f)

    Русский (Russian)
    инсулин

    Español (Spanish)
    n. - insulina

    Svenska (Swedish)
    n. - insulin

    中文(简体)(Chinese (Simplified))
    胰岛素

    中文(繁體)(Chinese (Traditional))
    n. - 胰島素

    한국어 (Korean)
    n. - 인슐린

    日本語 (Japanese)
    n. - インスリン

    العربيه (Arabic)
    ‏(الاسم) الأنسولين : هرمون يستعمل في معالجه مرض السكري‏

    עברית (Hebrew)
    n. - ‮אינסולין, הורמון מחומצות אמינו המיוצר בלבלב ומווסת את כמות הסוכר בדם‬


     
     

     

    Copyrights:

    Dictionary. The American Heritage® Dictionary of the English Language, Fourth Edition Copyright © 2007, 2000 by Houghton Mifflin Company. Updated in 2009. Published by Houghton Mifflin Company. All rights reserved.  Read more
    Britannica Concise Encyclopedia. Britannica Concise Encyclopedia. © 2006 Encyclopædia Britannica, Inc. All rights reserved.  Read more
    How Products are Made. How Products are Made. Copyright © 2002 by The Gale Group, Inc. All rights reserved.  Read more
    Sci-Tech Encyclopedia. McGraw-Hill Encyclopedia of Science and Technology. Copyright © 2005 by The McGraw-Hill Companies, Inc. All rights reserved.  Read more
    World of the Body. The Oxford Companion to the Body. Copyright © 2001, 2003 by Oxford University Press. All rights reserved.  Read more
    Food and Nutrition. A Dictionary of Food and Nutrition. Copyright © 1995, 2003, 2005 by A. E. Bender and D. A. Bender. All rights reserved.  Read more
    Food and Fitness. Food and Fitness: A Dictionary of Diet and Exercise. Copyright © 1997, 2003 by Oxford University Press. All rights reserved.  Read more
    Drug Info. Gold Standard. Copyright © 2008 by Gold Standard. All rights reserved.  Read more
    Sports Science and Medicine. The Oxford Dictionary of Sports Science & Medicine. Copyright © Michael Kent 1998, 2006, 2007. All rights reserved.  Read more
    Columbia Encyclopedia. The Columbia Electronic Encyclopedia, Sixth Edition Copyright © 2003, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/ Read more
    Health Dictionary. The New Dictionary of Cultural Literacy, Third Edition Edited by E.D. Hirsch, Jr., Joseph F. Kett, and James Trefil. Copyright © 2002 by Houghton Mifflin Company. Published by Houghton Mifflin. All rights reserved.  Read more
    Veterinary Dictionary. Saunders Comprehensive Veterinary Dictionary 3rd Edition. Copyright © 2007 by D.C. Blood, V.P. Studdert and C.C. Gay, Elsevier. All rights reserved.  Read more
    Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Insulin" Read more
    Translations. Copyright © 2007, WizCom Technologies Ltd. All rights reserved.  Read more